Abstract 1450P
Background
Liver metastases create a unique immunosuppressive microenvironment in patients with advanced non-small cell lung cancer (aNSCLC) and are associated with poorer outcomes when treated with chemoimmunotherapy, especially in non-squamous (ns-) aNSCLC.
Methods
We retrospectively analyzed data from IMpower150 and IMpower130, which included patients with ns-aNSCLC without EGFR/ALK/KRAS alterations, treated with first-line chemotherapy (CT) with/out atezolizumab (CT+IT) and/or bevacizumab (CT+IT+AA, CT+AA). Data was available on the VIVLI platform.
Results
Out of the 1,523 evaluable patients, 20.4% (n=311), 46.4% (n=707), 19.7% (n=300), and 13.4% (n=205) received CT+IT+AA, CT+IT, CT+AA, and CT, respectively. 13.9% (n=212) of the patients had liver metastases (LM). LM were associated with lower serum albumin and higher lactate dehydrogenase levels, a greater number of metastatic sites (all p<0.001) and poor outcomes across all treatment regimens except for patients treated with upfront CT+IT+AA (Table). In the overall population, CT+IT+AA achieved longer progression-free survival (HR for PFS: 0.74, p<0.001) but not overall survival (HR for OS: 0.91, p=0.38) compared to CT+IT. Of all included variables (age, smoking status, Lung Immune Prognostic Index (LIPI), albumin levels, ECOG performance status, and number of metastatic sites), only LM+ patients yielded substantial OS benefit of CT+IT+AA vs. CT+IT (HR for PFS: 0.44, p<0.001; HR for OS: 0.43, p=0.002, Table). No benefit of CT+AA over CT in patients with/out LM was observed. Table: 1450P
Impact of liver metastases on PFS and OS across all regimens and on response to CT+IT +/- AA
Impact of LM across regimens | |||||
Regimen | HR for OS (LM+ vs. LM-) | p-value | |||
CT | 1.8 (1.1-2.9) | 0.02 | |||
CT+AA | 2.2 (1.5-3.3) | <0.001 | |||
CT+IT | 2.5 (1.9-3.2) | <0.001 | |||
CT+IT+AA | 1.0 (0.6-1.7) | 0.94 | |||
Addition of bevacizumab to CT+IT | |||||
Overall | LM+ patients | ||||
CT+IT | CT+IT+AA | CT+IT | CT+IT+AA | ||
PFS | n | 707 | 311 | 103 | 39 |
Events | 548 | 210 | 90 | 27 | |
mPFS | 6.8 (6.0-7.1) | 8.3 (7.7-9.9) | 4.4 (3.9-5.4) | 8.0 (5.7-13.4) | |
6M-PFS | 53.4% | 67.0% | 28.4% | 58.3% | |
p | <0.001 | <0.001 | |||
OS | n | 707 | 311 | 103 | 39 |
Events | 336 | 128 | 74 | 16 | |
mOS | 18.6 (16.3-20.5) | 19.2 (16.8-NR) | 8.7 (6.5-11.2) | 16.8 (12.9-NA) | |
12M-OS | 63.6% | 67.5% | 36.7% | 65.5% | |
p | 0.35 | 0.002 |
Conclusions
LM are associated with poor outcomes in patients with aNSCLC treated with CT, CT+AA and CT+IT but not CT+IT+AA. The addition of bevacizumab to CT+IT improves outcomes (PFS and OS) in patients with liver metastases and helps correct its negative prognostic impact. The presence of liver metastasis may help in guiding treatment selection in first-line aNSCLC.
Clinical trial identification
Impower130: NCT02367781; Impower150: NCT02366143.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
S. Oudard: Financial Interests, Personal, Advisory Role: AstraZeneca, Astellas, Bayer, BMS, Ipsen, Janssen, Merck, MSD, Novartis, Pfizer, Sanofi; Financial Interests, Personal, Non financial benefits, Travel Accomodations and Expenses: Eisai, Roche; Financial Interests, Personal, Advisory Board: Roche. C. Thibault: Financial Interests, Personal, Advisory Board: Janssen, Astellas, Sanofi, Ipsen, Pfizer, Merck, MSD, BMS, AstraZeneca, AAA, Seagen; Financial Interests, Institutional, Funding: AstraZeneca, Sanofi. V.M. Albarran Artahona: Financial Interests, Invited Speaker: Merck; Financial Interests, Non financial benefits, Travel, accomodations, expenses: Janssen. C. Teixido: Financial Interests, Personal, Invited Speaker: AstraZeneca, Merck Sharp & Dohme, Roche Farma, Diaceutics, Pfizer, Janssen Oncology; Financial Interests, Personal, Advisory Board: AstraZeneca, Novartis; Financial Interests, Institutional, Research Grant: Novartis. B. Besse: Financial Interests, Institutional, Funding: 4D Pharma, AbbVie, Amgen, Aptitude Health, AstraZeneca, BeiGene, Blueprint Medicines, Boehringer Ingelheim, Celgene, Cergentis, Cristal Therapeutics, Daiichi Sankyo, Eli Lilly, GSK, Janssen, Onxeo, Ose Immunotherapeutics, Pfizer, Roche-Genentech, Sanofi, Takeda, Tolero Pharmaceuticals; Financial Interests, Institutional, Research Grant: Genzyme Corporation, Chugai Pharmaceutical, Eisai, Inivata, Ipsen, Turning Point Therapeutics. L. Mezquita: Financial Interests, Personal, Advisory Board: Takeda, AstraZeneca, Roche; Financial Interests, Personal, Invited Speaker: Roche, BMS, AstraZeneca, Takeda; Financial Interests, Personal, Research Grant, SEOM Beca Retorno 2019 : BI; Financial Interests, Personal, Research Grant, ESMO TR Research Fellowship 2019 : BMS; Financial Interests, Institutional, Research Grant, COVID research Grant: Amgen; Financial Interests, Institutional, Coordinating PI: INIVATA, Stilla. E. Auclin: Financial Interests, Advisory Board: Sanofi, Amgen. All other authors have declared no conflicts of interest.
Resources from the same session
1390P - Real-world characteristics, treatment patterns and outcomes of patients with advanced HER2/ERBB2-mutant non-small cell lung cancer (NSCLC) in France and Germany
Presenter: Petros Christopoulos
Session: Poster session 20
1391P - Capmatinib vs docetaxel as second- or third-line (2/3L) therapy in patients (pts) with METex14-mutated advanced NSCLC (aNSCLC): The GeoMETry-III trial
Presenter: Oscar Jose Juan Vidal
Session: Poster session 20
1392P - Safety and efficacy of crizotinib in MET mutated (METmut) advanced non-small cell lung Cancer (aNSCLC): Results from the Drug Rediscovery Protocol (DRUP)
Presenter: Karlijn Verkerk
Session: Poster session 20
1393P - Characteristics of MET gene and its relationship with TMB/MMR genes in Chinese NSCLC population
Presenter: Hong Yi Zhang
Session: Poster session 20
1394P - Real-world experience in treatment of patients with non-small cell lung cancer with BRAF and cMET Exon 14 skipping mutations
Presenter: Urska Janzic
Session: Poster session 20
1396P - HER2 testing pattern, characteristics of locally advanced or metastatic NSCLC patients by HER2 testing in France
Presenter: Didier Debieuvre
Session: Poster session 20
1397P - Prevalence, molecular characterization, and prognosis of MET–overexpressing non-small cell lung cancer (NSCLC) in a real-world patient cohort
Presenter: Jair Bar
Session: Poster session 20
1398P - Hepatotoxicity in patients (pts) with KRASG12C-mutated non-small cell lung cancer (NSCLC) treated with sotorasib after prior immunotherapy (IO)
Presenter: Sophie Ernst
Session: Poster session 20
1399P - Tumor-immune microenvironment analysis of de novo and acquired KRAS-mutated non-small cell lung cancer
Presenter: Joshua Reuss
Session: Poster session 20
1400P - Real-world effectiveness and safety of sotorasib in patients with KRAS G12C mutated metastatic non-small cell lung cancer (NSCLC): Results of the IFCT-2102 Lung KG12Ci study
Presenter: Marie Wislez
Session: Poster session 20